ArticleCurrent hypertension reports2003
Renal handling of angiotensin receptor blockers: clinical relevance.
Article in Current hypertension reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods.Clinical and experimental nephrology · 2009Trial
- Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics.Clinical and experimental nephrology · 2009Trial
- Pattern, frequency and factors associated with inappropriate high dosing in chronic kidney disease patients at a tertiary care hospital in Pakistan.BMC nephrology · 2023Article
- The kidney and hypertension: causes and treatment.Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Angiotensin receptor blockers: new considerations in their mechanism of action.Journal of clinical hypertension (Greenwich, Conn.) · 2006Review
- Hypertension, renal disease, and drug considerations.Journal of clinical hypertension (Greenwich, Conn.) · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin receptor blockers (ARBs), like angiotensin-converting enzyme (ACE) inhibitors, are commonly used in the setting of chronic kidney disease. The use of drugs in this class, or for that matter any drug in the renally compromised patient, should raise consideration of the impact of renal disease on the systemic elimination of the compound. Unlike most of the drugs in the ACE inhibitor class, the compounds making up the ARB class undergo significant hepatic elimination; thus, in the renal failure patient, they are not prone to relevant degrees of systemic accumulation with repetitive dosing. ARBs do not require dose adjustment in renal failure on the basis of their pharmacokinetic pattern; rather, dose reduction should be an empiric process dictated by having reached or exceeded the goal established for blood pressure reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.